Jun 4, 2025, 11:40
What Makes the CISTO Study Unique? Patient Voices, PCORI Funding, and Long-Term Vision
In this second part of OncoDaily Talks, Dr. Chandler Park speaks with Dr. John Gore, urologist at the University of Washington and Fred Hutchinson Cancer Center, about the ongoing impact of the CISTO study following its presentation at AUA 2025.
- Dr. Gore reflects on the AUA Plenary presentation and the effort to publish their findings
- He shares insights into the long-term follow-up plans with 2- and 5-year outcomes
- The origins of the CISTO study are explored, including its patient-driven design through the Bladder Cancer
- Advocacy Network (BCAN) and PCORI funding
- Dr. Gore explains why the study was designed as an observational cohort rather than a randomized trial, based on direct patient feedback
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 9, 2025, 19:54
Aug 9, 2025, 19:53
Aug 9, 2025, 19:37
Aug 9, 2025, 19:31
Aug 9, 2025, 19:17
Aug 9, 2025, 19:03
Aug 9, 2025, 18:55